A list of commonly used measurement tools for psoriasis management and clinical trials.
General
A simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages to measure disease severity and quality of life.
To express the severity of psoriasis by measuring redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
PGA: Physician's Global Assessment
Physician's assessment of the severity of disease based on a scale from clear to very severe.
Self-administered, patient-reported outcome measure (PRO) to assess symptom severity in chronic, plaque psoriasis.
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version as well as The Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
PEST is a validated screening tool for psoriatic arthritis (PsA) and it is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
A clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis
IPC does not endorse or accept any responsibility for the content of external websites.
congress coverage EADV 2019 Read the psoriasis highlights from the EADV 2019 congress learn more
Latest news Commentary: Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based studyOctober 23, 2020Commentary provided on this international moderate-severe psoriasis case series, where biologics use was associated with lower risk of COVID-19-related hospitalization than non-biologic systemic therapies, however further investigation is warranted due to potential selection bias and unmeasured confounding. PsoProtect registry data on first 200 casesOctober 15, 2020PsoProtect, the global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data so that it now includes the first 200 cases. Commentary: National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic DiseaseOctober 06, 2020IPC Founding President Alan Menter and IPC Councilor Ulrich Mrowietz discuss the new guidance on psoriasis care from the National Psoriasis Foundation COVID-19 Task Force. Psoriasis experts bust some myths about the diseaseOctober 05, 2020Christopher EM Griffiths and Mahira Hamdy El Sayed use science to counter misinformation about psoriasis. These two dermatologists discuss natural treatments for psoriasis, how lifestyle can affect the immune system, and the rosy future of psoriasis treatment. More News